Veracyte (NASDAQ:VCYT) EVP Annie Mcguire Sells 3,254 Shares of Stock

Veracyte, Inc. (NASDAQ:VCYT) EVP Annie Mcguire sold 3,254 shares of Veracyte stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $43.09, for a total transaction of $140,214.86. Following the completion of the sale, the executive vice president owned 131,160 shares in the company, valued at approximately $5,651,684.40. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Veracyte Stock Down 4.8%

Veracyte stock opened at $42.53 on Friday. Veracyte, Inc. has a 52-week low of $29.45 and a 52-week high of $60.91. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of 30.16 and a beta of 1.93. The firm has a 50-day moving average price of $50.64 and a two-hundred day moving average price of $43.12.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The company had revenue of $150.32 million for the quarter, compared to analyst estimates of $144.59 million. Veracyte had a net margin of 20.37% and a return on equity of 9.26%. Veracyte’s revenue was up 15.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.44 earnings per share. Research analysts expect that Veracyte, Inc. will post 1.32 earnings per share for the current year.

Trending Headlines about Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Institutional ownership trends remain supportive. Bank of America, Royal Bank of Canada and William Blair increased their positions, while Summit Creek Advisors and Deutsche Bank initiated new stakes. Analysts maintain a “Moderate Buy” consensus with an average price target of $54.33, above recent trading levels. Veracyte insider trading and institutional ownership report
• Neutral Sentiment: Veracyte’s most recent reported quarter showed earnings of $0.54 per share versus the $0.41 consensus estimate, while revenue rose 15.5% year over year to $150.32 million. These results provide a fundamental backdrop of continued growth, although they are not new developments in the latest disclosures.
• Negative Sentiment: EVP Annie McGuire sold 3,254 shares for approximately $140,215, CFO Rebecca Chambers sold 3,652 shares for about $157,401, and insider Phillip Febbo sold 13,110 shares valued at roughly $564,386. Each transaction was executed through a 10b5-1 plan to cover taxes, and the sellers retained substantial positions, limiting the signal that management is broadly abandoning the stock. Veracyte executive stock sale filing
• Negative Sentiment: Director Muna Bhanji separately sold 1,864 shares for approximately $80,096, reducing her position by 4.18%. The sale was also pre-arranged, but the cluster of insider transactions may reinforce short-term caution among investors. Muna Bhanji Veracyte stock sale

Wall Street Analyst Weigh In

Several brokerages have weighed in on VCYT. Needham & Company LLC lifted their target price on Veracyte from $57.00 to $69.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings cut Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, August 24th. Zacks Research raised Veracyte from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 11th. Guggenheim raised their price target on Veracyte from $45.00 to $65.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Wolfe Research assumed coverage on shares of Veracyte in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Veracyte has a consensus rating of “Moderate Buy” and a consensus target price of $54.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its position in Veracyte by 14.7% in the first quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company’s stock worth $46,669,000 after purchasing an additional 185,929 shares during the period. Summit Creek Advisors LLC acquired a new position in shares of Veracyte during the 2nd quarter valued at $6,986,000. William Blair Investment Management LLC raised its stake in shares of Veracyte by 16.6% in the 4th quarter. William Blair Investment Management LLC now owns 790,425 shares of the biotechnology company’s stock worth $33,277,000 after buying an additional 112,516 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Veracyte by 66.4% in the 1st quarter. Royal Bank of Canada now owns 573,096 shares of the biotechnology company’s stock worth $18,459,000 after buying an additional 228,720 shares in the last quarter. Finally, Great Lakes Advisors LLC acquired a new stake in shares of Veracyte in the second quarter valued at $3,851,000.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.